As a hot target in tumor immunotherapy, B7-H3 has not only attracted fierce competition among multiple ADC (Antibody-Drug Conjugate) developers but has also garnered significant attention due to the tumultuous commercialization journey of one specific radiopharmaceutical—Omburtamab. From the technology transfer at MSK and the FDA's unanimous rejection based on a single-arm trial, to pipeline restructuring and continued exploration, this case reflects the complex interplay between scientific rigor and commercial strategy in new drug development. Notably, such narratives are far from isolated incidents in the global innovative drug landscape...

B7-H3 (CD276) is a key member of the B7 immune checkpoint family. As a transmembrane immunomodulatory molecule, it exhibits distinct pathological specificity within the tumor microenvironment. Studies indicate that B7-H3 is specifically expressed in various malignant tumor cells and tumor-infiltrating immune cells (e.g., monocytes, dendritic cells, myeloid-derived suppressor cells [MDSCs], neutrophils, macrophages, B cells, and activated T cells), while its expression in normal tissues is extremely low and strictly restricted. This significantly dysregulated expression pattern is closely associated with tumor immune evasion, malignant proliferation, invasion, and metastasis. Consequently, B7-H3 serves not only as a critical biomarker for assessing tumor malignancy but also as a highly promising therapeutic target due to its high selectivity in tumor tissues.

Expression Distribution of B7-H3:

Structure of B7-H3:

B7-H3 (CD276) is a type I transmembrane glycoprotein belonging to the B7 immune checkpoint family. Its structure consists of three parts: an extracellular domain, a transmembrane domain, and a highly diverse intracellular domain.

• Extracellular Domain: Human B7-H3 exists in two isoforms (2IgB7-H3 and 4IgB7-H3). The 4Ig isoform, composed of two pairs of identical immunoglobulin variable (IgV) and constant (IgC) domains, is the predominant form expressed in the tumor microenvironment. In contrast, 2IgB7-H3 consists of a single pair of IgV-like and IgC-like domains. Murine B7-H3 expresses only the 2Ig isoform, containing a single pair of IgV and IgC domains.
• Transmembrane Domain: Connects the extracellular and intracellular domains, anchoring the molecule to the cell membrane.
• Intracellular Domain: Contains only 45 amino acids and lacks known signaling motifs, suggesting its function may rely on interactions with other proteins or post-translational modifications.

Functions and Disease Associations of B7-H3:

Its oncogenic mechanism presents dual characteristics. On one hand, B7-H3 constructs an immunosuppressive microenvironment by inhibiting the cytotoxic activity of T cells, hindering interferon-gamma (IFN-γ) secretion, promoting regulatory T cell (Treg) differentiation, and weakening natural killer (NK) cell function. On the other hand, its non-immune-dependent functions can activate oncogenic signaling pathways such as JAK/STAT and PI3K/AKT, driving tumor cell proliferation, epithelial-mesenchymal transition (EMT), and angiogenesis, while simultaneously enhancing tumor resistance to chemotherapy and distant metastatic capability. Notably, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) developed against specific glycosylation epitopes of B7-H3 have demonstrated significant anti-tumor activity in preclinical studies. Furthermore, CAR-T therapies targeting B7-H3 have achieved breakthrough progress in the treatment of solid tumors. These advancements position B7-H3 as one of the most translationally valuable molecular targets in current tumor immunotherapy.

As the world's first B7-H3-targeting Radiopharmaceutical Drug (RDC), the development journey of Omburtamab exemplifies a paradigm of strategic collaboration in innovative drug development. Developed by Memorial Sloan Kettering Cancer Center (MSK) based on its breakthrough antibody 8H9, the drug achieves precise radiotherapy for Central Nervous System/Leptomeningeal Metastatic Neuroblastoma (CNS/LM) through Iodine-131 labeling. In 2015, Y-mAbs Therapeutics reached a global exclusive licensing agreement with MSK, officially initiating the clinical translation of this project.

Based on its potential to address unmet needs in pediatric oncology, the drug received early global regulatory endorsement: In March 2017, the EMA granted it Orphan Drug Designation, providing 10 years of market exclusivity for the leptomeningeal metastasis neuroblastoma indication. In June of the same year, the FDA further granted Breakthrough Therapy Designation, advancing its application in second-line and subsequent treatments for pediatric neuroblastoma via an accelerated review pathway. These milestones, coupled with the exclusive licensing cooperation in Greater China signed with Sinocelltech in 2020, not only made Omburtamab a benchmark case for multinational pharmaceutical companies positioning in Asian radiopharmaceuticals but also thrust the B7-H3 targeted radiotherapy track into the industry spotlight. At that time, with dazzling clinical data and rising capital enthusiasm, it appeared poised to be a game-changer in the field of pediatric targeted tumor therapy.

However, its development journey became a classic cautionary tale regarding clinical design in innovative drugs. In October 2022, the FDA raised scientific concerns regarding the selection of historical control groups in the single-arm trial—patient data spanning a decade contained key variable biases such as geography (USA, Germany) and lines of therapy. As an external clinical control for a single-arm study, the data could not provide a reasonable comparison across time, location, and prior treatment lines. Following survival benefit analysis, the FDA Advisory Committee deemed the efficacy evidence insufficient, ultimately closing the approval pathway with a unanimous 16:0 vote against approval and a subsequent Complete Response Letter (CRL). This setback not only led to the termination of Omburtamab's multi-nuclide exploration path (including the ¹²⁴I PET diagnostic product and ¹⁷⁷Lu therapeutic product) but also triggered severe volatility in the capital market, causing a cliff-like plunge in stock price and evaporating over 80% of its market value...

On January 18, 2023, investors filed a class-action lawsuit demanding compensation for investment losses caused by misleading conduct. Investors alleged that the company exaggerated the likelihood of FDA approval for the drug and failed to adequately disclose the risk that the drug might not be approved. Such misleading behavior potentially led investors to make decisions based on incorrect information. Ultimately, Y-mAbs agreed to pay $19.65 million to settle with shareholders, resolving the litigation. This indicates the company acknowledged potential misconduct in information disclosure and was willing to offer financial compensation to appease investor dissatisfaction.

A dramatic turning point emerged following strategic restructuring: The company decisively divested non-core assets (including the GD2-GD3 vaccine and CD33 bispecific antibody) and streamlined its team by 35%, extending its cash runway to 2027. Simultaneously, R&D focus shifted toward the nuclear drug delivery technology SADA (Stepwise Avidin-Dotin System, a pretargeted radioimmunotherapy technology; see image below for principle and current pipeline composition). This platform utilizes modular design to separate "pretargeting" from "nuclide therapy," significantly reducing radiation damage to normal tissues. Its first GD2-SADA project initiated Phase 1 clinical trials for solid tumors in 2023. With the radiopharmaceutical sector becoming a hotspot for MNC M&A (e.g., BMS acquiring RayzeBio for $4.1 billion), combined with cash flow support from Danyelza (GD2 mAb) sales growing 71% YoY to $84.3 million, and Y-mAbs announcing the appointment of Dr. Mary Tagliaferri (formerly of RayzeBio) to the board in 2024, the capital market has reignited expectations for Y-mAbs' technology translation, driving a rebound in its stock price.

The application for ¹³¹I-omburtamab relied primarily on two single-arm studies: Study 03-133 and Study 101. Detailed introductions follow:

Study 03-133（NCT00089245）

Design: A single-arm, single-center Phase I trial designed to explore the safe dose and preliminary efficacy of ¹³¹I-omburtamab in patients with relapsed/refractory neuroblastoma with central nervous system (CNS)/leptomeningeal metastases.

Through survival data comparison, long-term follow-up results, and statistical analysis, the study strongly supported that CRIT combined with radiotherapy could significantly improve the prognosis of patients with CNS-relapsed neuroblastoma, breaking through the survival bottleneck of traditional treatments:

• Median Progression-Free Survival (PFS): NB patients receiving CRIT achieved a median PFS of 7.5 years, whereas historical data indicated that the median survival for neuroblastoma patients with CNS relapse is typically <6 months (citing Matthay et al., 2003, where median OS <6 months).
• Overall Survival (OS): The median OS was 11.1 years, significantly superior to traditional treatments (literature suggests the mortality rate for CNS-metastatic NB patients approaches 100%).
• Long-term Survivors: 47% (7/15) of NB patients survived progression-free for over 13-17 years after CRIT, with only 13% (2/15) experiencing CNS recurrence (other causes of death were mostly systemic recurrence or chemotherapy toxicity).

Despite these findings, the FDA's stance on its marketing application was critical. Due to the use of an external control, the FDA considered there to be significant differences between the study population and the control group in terms of treatment intensity (e.g., radiotherapy, chemotherapy regimens), geography (USA vs. Germany), and time (long study span). Consequently, the survival difference could not be reliably attributed to the drug.

Study 101（NCT03275402）

FDA Declares Failure of ¹³¹I‑omburtamab Marketing Application

In December 2022, the FDA issued a Complete Response Letter (CRL) pointing out core deficiencies in Y-mAbs' marketing application for ¹³¹I‑omburtamab:

• Insufficient evidence of efficacy (lack of quantitative endpoints such as objective response rate, questionable attribution of survival benefit, and poorly designed external control group).
• Limitations in trial design (single-arm study unable to exclude confounding factors, insufficient validation of dose-efficacy relationship and impact of anti-drug antibodies).
• Insufficient long-term safety data (unclear radiation-related potential risks, inadequate risk-benefit assessment).

The FDA emphasized that existing data were difficult to support regulatory approval, requiring supplementary multicenter randomized controlled trials to confirm efficacy, optimized pharmacokinetic studies, and long-term follow-up to verify safety—especially the need to establish a stricter benefit-risk framework in pediatric patients.

Fundamentally, this outcome may have been inevitable. Since 2016, the FDA had repeatedly warned Y-mAbs that the patient population submitted in its clinical trials lacked comparability with the Childhood Brain Tumor Consortium Registry (CGCCR) population, and this was not a "new finding" as the company claimed. In the January 2022 discussion on resubmitting the BLA, the FDA reiterated that the CGCCR data had fundamental flaws (e.g., lack of a control group for patients receiving craniospinal irradiation), and Y-mAbs' analysis was criticized by the FDA as "arbitrary" and failing to adequately address key concerns. Despite the FDA explicitly requesting a reliable control or the initiation of an "alternative clinical development plan," Y-mAbs continued to claim to investors that it was "aligned with the FDA," possessed "complete data," and that the "application was progressing smoothly," attempting to mask substantial disagreements in regulatory communications. Y-mAbs positioned omburtamab as a disruptive therapy for CNS tumors, gambling between commercial ambition and scientific rigor. Over-reliance on single-arm data became a strategic misjudgment, reflecting the eternal contradiction in new drug development among speed, cost, and strength of evidence.

Data Source: DOI: https://doi.org/10.2967/jnumed.123.266365

Key results showed: Significant retention of radioactive activity within the tumors of all patients (mean residence time 24.9 hours, radiation dose equivalent 353±181 mSv/MBq), persisting until the last imaging (up to 10 days); extremely low whole-body and blood exposure (whole-body dose equivalent 0.69±0.28 mSv/MBq, blood dose 0.27±0.21 mGy/MBq), with minimal distribution in normal tissues; whole-body clearance followed a mono-exponential model (biological half-life 62.7 hours), while blood clearance followed a bi-exponential model ( αα -phase half-life 22.2 hours, ββ -phase 155 hours). This method achieves high-dose local tumor radiation via CED technology (significantly improving the tumor-to-normal tissue dose ratio), while real-time PET/CT monitoring confirms its theranostic potential, providing a highly efficient and low-toxicity new treatment strategy for DIPG.